baji live casino
baji live casino
James, Quigley and Hayes combine for 59 points as No. 20 NC State women beat Coastal Carolina 89-68SINGAPORE , Nov. 30, 2024 /PRNewswire/ -- Amber DWM Holding Limited ("Amber DWM"), the holding entity of Amber Group's digital wealth management business, known as Amber Premium ("Amber Premium"), today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with iClick Interactive Asia Group Limited ("iClick" or the "Listco") (NASDAQ: ICLK ) and Overlord Merger Sub Ltd. ("Merger Sub"), a Cayman Islands exempted company and a direct, wholly owned subsidiary of the Listco. Under the Merger Agreement, Merger Sub will merge with and into Amber DWM, with Amber DWM continuing as the surviving entity and becoming a wholly-owned subsidiary of the Listco (the "Merger"). Amber DWM's shareholders will exchange all of their issued and outstanding share capital for a mix of newly issued Class A and Class B ordinary shares of the Listco on the terms and conditions set forth therein in a transaction exempt from the registration requirements under the Securities Act of 1933. Wayne Huo , Chief Executive Officer and Director of Amber DWM , said: " We are thrilled to embark on this transformative journey with iClick. This merger represents a significant milestone, bringing together Amber Premium's expertise in digital wealth management and iClick's innovative marketing technology. Together, we aim to redefine the digital financial ecosystem, delivering unparalleled value to our clients and stakeholders. By bridging the worlds of blockchain, fintech and digital marketing, we are unlocking new opportunities to revolutionize how value is created and exchanged in the digital economy ." The transaction values Amber DWM at US$360 million and the Listco at US$40 million by equity value on a fully diluted basis (assuming completion of certain restructuring as set forth in the Merger Agreement). Upon closing of the Merger (the "Closing"), the Amber DWM shareholders and the Listco shareholders (including holders of ADSs) will own approximately 90% and 10%, respectively, of the outstanding shares of the combined company, or 97% and 3% voting power, respectively. The Merger Agreement also contemplates that, upon the Closing, the Listco will change its name to "Amber International Holding Limited" and adopt the tenth amended and restated memorandum and articles of association of the Listco, in each case immediately before the effective time of the Merger (the "Effective Time"), following which the authorized share capital of the Listco shall only consist of Class A ordinary shares and Class B ordinary shares (with different voting powers but equal economic rights), a par value of US$0.001 each. Please refer to the Merger Agreement filed as Exhibit 99.2 to the Form 6-K furnished by the Listco to the SEC on November 29, 2024 for more details. The Listco's board of directors (the "Board") approved the Merger Agreement and other transaction documents, including but not limited to the voting agreement entered into by and among certain shareholders of the Listco (who holds approximately 36% of the outstanding shares representing 71% voting power of the Listco as of the date of this press release), the Listco and Amber DWM (the "Voting Agreement") (collectively, the "Transaction Documents"), and the transactions contemplated thereunder (the "Transactions"), with the assistance of its financial and legal advisors. The Board also resolved to recommend that the Listco's shareholders vote to authorize and approve the Transaction Documents and the Transactions when they are submitted for shareholder approval. In connection with the Transaction, each of the shareholders of Amber DWM immediately prior to the consummation of the Merger is entering into a lock-up agreement with the Listco pursuant to which they have agreed not to transfer the shares received in consideration of the Merger for a period of 12 months following the Merger closing. The completion of the Transactions is subject to the satisfaction of closing conditions set forth in the Merger Agreement, including, among other things, receipt of the Listco's shareholder approval and regulatory/stock exchange approvals (if applicable). The Merger Agreement provides for a long-stop date for any party to terminate the agreement if the Merger is not completed by June 30, 2025 . " This merger represents a transformative opportunity to broaden our business portfolio by integrating Amber Premium's state-of-the-art digital wealth management solutions. By uniting iClick's robust data analytic and enterprise software expertise with Amber Premium's advanced digital wealth management services, we aim to unblock synergies between traditional finance and the rapidly evolving digital asset ecosystem, particularly benefitting corporate and high net worth individual clients ", said Mr. Jian Tang , Chairman, Chief Executive Officer and Co-Founder of iClick . The foregoing description of the Merger Agreement and the Voting Agreement does not purport to be complete and is qualified in its entirety to the full text of the Merger Agreement and the Voting Agreement, which are filed as Exhibits 99.2 and 99.3 to the Form 6-K furnished by the Listco to the SEC on 29, 2024, respectively. Simpson Thacher & Bartlett LLP is serving as U.S. legal counsel to Amber DWM. Cleary Gottlieb Steen & Hamilton LLP is serving as U.S. legal counsel to iClick. About Amber Premium Amber Premium, the business brand behind Amber DWM Holding Limited, is a leading digital wealth management platform offering private banking-level solutions tailored for the dynamic crypto economy. Serving a premium clientele of esteemed institutions and qualified individuals, Amber Premium develops and supports innovative digital wealth management products. Its institutional-grade access and operations makes it the top choice for one-stop digital wealth management services, providing tailored, secure solutions that drive growth in the Web3 economy. About iClick Interactive Asia Group Limited Founded in 2009, iClick Interactive Asia Group Limited (NASDAQ: ICLK ) is a renowned online marketing and enterprise solutions provider in Asia . With its leading proprietary technologies, iClick's full suite of data-driven solutions helps brands drive significant business growth and profitability throughout the full consumer lifecycle. For more information, please visit https://ir.i-click.com . Safe Harbor Statement This press release contains certain "forward-looking statements." These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. The words "will," "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements. Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from the expectations as a result of a variety of factors. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which are hard to predict or control, that may cause the actual results, performance, or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the proposed transaction, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iii) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the Listco, Amber DWM or the combined entity; (iv) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (v) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Listco's securities; (vi) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Amber DWM or the combined entity to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (vii) any changes in the business or operating prospects of Amber DWM and the combined entity or their businesses; (viii) changes in applicable laws and regulations; and (ix) risks relating to Amber DWM's and the combined company's ability to enhance their services and products, execute their business strategy, expand their customer base and maintain stable relationship with their business partners. A further list and description of risks and uncertainties can be found in the proxy statement that will be filed with the SEC by the Listco in connection with the proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Listco, Amber DWM and their respective subsidiaries and affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation. No Offer or Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Amber DWM, the Listco or the combined company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. Participants in the Solicitation The Listco, Amber DWM and their respective directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of the Listco in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement pertaining to the proposed transaction when it becomes available for the proposed transaction. Additional Information and Where to Find It The Listco will file with the SEC and mail to its shareholders a proxy statement in connection with the proposed transaction. Investors and securityholders are urged to read the proxy statement when it becomes available because it will contain important information regarding the proposed arrangement. You may access the proxy statement (when available) and other related documents filed by the Listco with the SEC at the SEC's website at www.sec.gov . You also may obtain the proxy statement (when it is available) and other documents filed by the Listco with the SEC relating to the proposed arrangement for free by accessing the Listco's website at ir.i-click.com. SOURCE Amber GroupUTSA 78, HOUSTON CHRISTIAN 71
Taylor Swift sends fans in frenzy with highly anticipated Easter EggGodzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories. Likewise, huge companies of today were once much smaller (unless perhaps they were spin-offs). Investors who spotted them early had opportunities to make fortunes. Can you still find such monsters in the making? Three Motley Fool contributors think so. Here's why they think biotech stocks CRISPR Therapeutics ( CRSP 3.44% ) , Summit Therapeutics ( SMMT 3.15% ) , and Viking Therapeutics ( VKTX 1.86% ) could become much larger. An underrated stock with two approvals under its belt David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet. But with CRISPR Therapeutics, you already have a stock that has an approved treatment -- it simply isn't far along in its rollout. In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals . It was approved as a treatment for sickle cell disease for patients 12 years and older. Then, a month later, it was also approved to treat people with transfusion-dependent beta-thalassemia (for the same age group). Casgevy can be a game changer for patients with these rare blood disorders as it is a one-time functional cure. CRISPR will share in the profits with Vertex on Casgevy (collecting 40% of them), which could potentially help the company get to profitability. Currently, its operations are well funded with CRISPR reporting more than $1.9 billion in cash and marketable securities as of the end of September. For a business that has burned through $92.7 million in cash over the past nine months, that can provide it with a lot of runway and time to grow its operations and work on other treatments in its pipeline. At a modest market cap of just $4 billion, there's a lot of room for CRISPR to get a whole lot more valuable in the future as it scales its operations and Casgevy starts to generate revenue. Buying the healthcare stock now can be a great move for long-term investors. Already showing monster potential Keith Speights (Summit Therapeutics): It's practically unheard of for a company with no product on the market to have a market cap of $14 billion. But Summit Therapeutics is no ordinary company. The drugmaker in-licensed cancer immunotherapy ivonescimab in January 2023. That has turned out to be a brilliant move in retrospect. Earlier this year, Akeso (which originally developed ivonescimab) announced the drug beat Merck 's blockbuster immunotherapy Keytruda in a head-to-head late-stage study targeting non-small cell lung cancer (NSCLC). How big of a deal was this news? Consider that Keytruda was the world's best-selling drug last year, raking in sales of around $25 billion. Summit owns the commercial rights in the U.S., Canada, and Europe of a cancer immunotherapy that could be even more powerful than Keytruda. Granted, Summit can't ride on the clinical success achieved by Akeso. The company must conduct its own clinical studies to hopefully win approval for ivonescimab in the U.S. and elsewhere. However, that's exactly what it's doing with initial results expected from a late-stage study of the immunotherapy as a second-line treatment for NSCLC in mid-2025. Summit is also evaluating ivonescimab in another late-stage trial as a first-line treatment for NSCLC. Wall Street's consensus is that Summit's share price could soar more than 40% over the next 12 months. I'm not sure if this price target will be achieved, but it wouldn't surprise me if that's an overly pessimistic goal assuming the company announces positive clinical results next year. Summit Therapeutics is already showing monster potential. I suspect it will fulfill that potential if ivonescimab wins U.S. regulatory approval. You can still get in on the ground floor Prosper Junior Bakiny (Viking Therapeutics): Weight-loss management is the hottest therapeutic area in the pharmaceutical industry right now. Although the companies dominating the field are the usual suspects, a notable mid-cap biotech called Viking Therapeutics is looking to make waves in this market. Viking's lead anti-obesity candidate, VK2735, reported excellent results in phase 2 studies. It might still be a few years until VK2735 earns regulatory approval, but Viking Therapeutics is not a one-trick pony. The company is working on an oral version of VK2735 -- something many patients would choose over the weekly injections the original formulation comes with. Furthermore, Viking Therapeutics has another promising weight-loss candidate in preclinical studies . And I have yet to mention the drugmaker's VK2809, an investigational medicine for metabolic dysfunction-associated steatohepatitis -- a liver disease with obesity as a risk factor -- and Viking's VK0214, an investigational therapy for a rare nervous system disease called X-linked adrenoleukodystrophy. Many smaller drugmakers tend to hyperfocus on a single medicine, a strategy that allows them to avoid spreading their resources thin. Viking Therapeutics, though, is taking a different approach. The company is showing signs of one of the most critical factors successful biotechs need: innovation. There are still risks involved here. Viking's late-stage studies for VK2735 could flop. However, the company is looking increasingly attractive. In a decade, it could join the ranks of highly successful drugmakers. It's not too late to get in on the ground floor.No. 22 Xavier faces South Carolina St., eyes rebound from lone loss
Ryan Day Is Getting Ripped For Horrendous Playcalling vs. Michigan
Jason McDonald Consulting Announces Winter 2025 Online Digital Marketing Course via Stanford Continuing Studies
ITV's I'm A Celebrity viewers defend Oti Mabuse against 'mum-shaming' trollsMiddle East latest: Israeli ambassador to US says Hezbollah ceasefire deal could come 'within days'
This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here . Philadelphia news 24/7: Watch NBC10 free wherever you are Markets rally U.S. stocks saw a broad rally on Monday with major indexes hitting record highs. The pan-European Stoxx 600 closed near the flatline . UniCredit , an Italian bank, offered to buy its domestic rival Banco BPM for roughly 10 billion euros ($10.5 billion). UniCredit has also been eyeing German lender Commerzbank . Wall Street likes Bessent Scott Bessent, President-elect Donald Trump's pick for U.S. Treasury secretary, has got a big thumbs up from the stock as well as bond markets . Wall Street strategists heaped praise on Bessent; global analysts also think Trump's pick is favorable for markets . Intel's close to clinching deals The U.S. CHIPS and Science Act office is nearing a deal with Intel , which would award the chipmaker with a grant worth around $8.5 billion , according to a source close to the matter. The Department of Defense is also poised to award Intel a $3 billion contract to manufacture chips . Those are some bright spots in Intel's difficult year . Bitcoin struggles to break barrier After hovering near the $100,000 mark, bitcoin lost some momentum and has dropped to $94,228.47, according to Coin Metrics. Investors are likely taking profit, said Andre Dragosch, head of research for Europe at Bitwise. There's also "a ton of leverage in the system," Mark Novogratz, CEO of digital asset management firm Galaxy Digital, told CNBC. [PRO] How to invest $500,000 in 2025 In 2025, Trump, with his policies that promise to shake up the economy, will be in the White House; the U.S. Federal Reserve will continue tweaking rates; and Nvidia will be delivering its next-generation Blackwell chips. CNBC Pro spoke with wealth managers to find out how investors should invest $500,000 in the rocky year ahead . The Trump rally appears to be shifting into high gear. This time, it's revved up by Trump's Treasury secretary pick — Scott Bessent. Investors like Bessent because, as the founder of hedge fund Key Square Group, he brings to the job an understanding of Wall Street and is presumably supportive of markets. Moreover, Bessent has expressed that he prioritizes controlling inflation even amid policies designed to support domestic growth. "I would recommend that tariffs be layered in gradually," Bessent told CNBC earlier this month before his nomination. Unlike earlier Trump rallies, in which particular assets linked to Trump's policies — bank stocks, small-cap stocks and bitcoin — reaped disproportionate gains, yesterday's rise in markets was broad. The S&P 500 rose 0.3%, in a move that saw more than 3 of 4 stocks in the index trading higher. The Dow Jones Industrial Average climbed 0.99%, extending its string of record highs, and the Nasdaq Composite added 0.27%. It wasn't just large-caps that were lifted by Bessent's nomination. Small-cap stocks performed even better, probably because Bessent has expressed support for Trump's economic agenda, which would benefit smaller, domestically oriented companies. The Russell 2000 index of small- and mid-caps gained 1.47%, its sixth positive session in a row. It closed at a new high, exceeding its record set in 2021. The bond market also reacted positively to the news. Yield on the 10-year Treasury fell more than 14 basis points. "You can't ask for a better reception from the market," said Quincy Krosby, chief global strategist at LPL Financial. "This is the market applauding." U.S. markets will be closed on Thursday for Thanksgiving. Bessent might be one of the things for which investors will be grateful. — CNBC's Alex Harring and Hakyung Kim contributed to this report.Pregnant Charlotte Crosby ‘rushed to hospital’ days after home robbery attempt
- Previous:
- Next: bet365 live casino
Zi
,!6#GT
yʧ66u@?NA! I^HݒWZac[A?x3b,,ܨUO퀝+Z63Z">